Clinical Trials · NCT07801898
Neoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast Cancer
- Phase
- Phase 2
- Recruitment status
- Not Yet Recruiting
- Sponsor
- The Second Hospital of Anhui Medical University
- Enrollment
- 36
- Start date
- Sep 2026
- Locations
- 1 site, China
- Primary endpoint
- Objective Response Rate (ORR)